[Epirubicina neoadyuvante con o sin docetaxel secuencial en el tratamiento del cáncer de mama avanzado: evaluación de la respuesta patológica completa y tolerabilidad de la quimioterapia].

Objective: To assess the pathological complete response (pCR) rate after neoadjuvant chemotherapy (NC) with anthracyclines with or without taxanes in management of locally advanced breast cancer (LABC).

Method: Patients with LABC were included. A cohort received four cycles of 5-fluorouracil [FEC] (FEC 500 mg/m, epirubicin 75 mg/m, cyclophosphamide 500 mg/m) every 3 weeks followed by four cycles of docetaxel (D) 75 mg/m as 1 h infusion intravenous every 3 weeks.